{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:07:36Z","timestamp":1790446056173,"version":"4.1.0"},"reference-count":98,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Tuberculosis remains the biggest global killer from infectious causes, with an estimated 1.25 million deaths per year. The quadruple drug regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol has been standard therapy for 40 years, with good outcomes in patients with drug susceptible tuberculosis who are able to tolerate the drug regimen. However, the frequency of adverse drug reactions and emergence of drug resistant tuberculosis has created demand for new treatment strategies: there is now a surge in novel tuberculosis agents and regimens entering human trials. For decades, drug resistant tuberculosis required at least 18 months of second line and third line combination treatments that included injectable agents. In 2022, in response to a growing body of trial evidence, the World Health Organization (WHO) introduced six\u2009month and nine\u2009month all oral regimens for pulmonary drug resistant tuberculosis in specific settings. These encompass agents in the bedaquiline-pretomanid-linezolid\/moxifloxacin regimen, as well as repurposed and novel agents such as clofazimine and delamanid. In addition, a large number of novel antimicrobial and host directed treatments are progressing to late stage clinical trials for tuberculosis, raising the prospect of shorter, more efficacious, and better tolerated treatments. This review summarises the agents and regimens recommended in the latest consolidated WHO treatment guidelines for tuberculosis (2025), including a synopsis of the evidence base for their safety, efficacy, and cost effectiveness. It also outlines the antimicrobial and host directed treatments that have entered phase 2-4 clinical trials for pulmonary tuberculosis in adults.<\/jats:p>","DOI":"10.1136\/bmjmed-2025-001836","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:25:15Z","timestamp":1776864315000},"page":"e001836","source":"Crossref","is-referenced-by-count":1,"title":["Current and emerging therapies for pulmonary tuberculosis in adults"],"prefix":"10.1136","volume":"5","author":[{"given":"Amira","family":"Mahmood","sequence":"first","affiliation":[{"name":"Northern Health and Social Care Trust, Ballymena, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Bilal","family":"Ashfaq","sequence":"additional","affiliation":[{"name":"Northern Health and Social Care Trust, Ballymena, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Drain","sequence":"additional","affiliation":[{"name":"HCS Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5528-3695","authenticated-orcid":false,"given":"Eoin","family":"Melby","sequence":"additional","affiliation":[{"name":"HCS Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hunter","sequence":"additional","affiliation":[{"name":"HCS Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-5391","authenticated-orcid":false,"given":"Timothy David","family":"Shaw","sequence":"additional","affiliation":[{"name":"HCS Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK"},{"name":"Queen\u2019s University Belfast Wellcome-Wolfson Institute for Experimental Medicine, Belfast, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026061123350682000_5.1.e001836.1","unstructured":"World Health Organisation . Global tuberculosis report. 2024."},{"key":"2026061123350682000_5.1.e001836.2","unstructured":"Tuberculosis (TB) notifications reported to enhanced TB surveillance systems: UK, 2000 to 2023 - gov.UK. Available: https:\/\/www.gov.uk\/government\/statistics\/tuberculosis-tb-notifications-reported-to-enhanced-tb-surveillance-systems-uk-2000-to-2023\/tuberculosis-tb-notifications-reported-to-enhanced-tb-surveillance-systems-uk-2000-to-2023#drug-resistance-by-country-over-time [Accessed 22 May 2025]."},{"key":"2026061123350682000_5.1.e001836.3","unstructured":"UK Health Security Agency . Tuberculosis (TB) notifications reported to enhanced TB surveillance systems: UK, 2000 to 2023. 2000."},{"key":"2026061123350682000_5.1.e001836.4","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026061123350682000_5.1.e001836.5","unstructured":"TB diagnosis, microbiology and drug resistance in England, 2021 - gov.UK. Available: https:\/\/www.gov.uk\/government\/publications\/tuberculosis-in-england-2022-report-data-up-to-end-of-2021\/tb-diagnosis-microbiology-and-drug-resistance-in-england-2021 [Accessed 22 May 2025]."},{"key":"2026061123350682000_5.1.e001836.6","unstructured":"World Health Organisation . Consolidated guidelines on tuberculosis treatment. module 4: treatment and care. 2025."},{"key":"2026061123350682000_5.1.e001836.7","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061123350682000_5.1.e001836.8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","article-title":"Tuberculosis","volume":"405","author":"Trajman","year":"2025","journal-title":"The Lancet"},{"key":"2026061123350682000_5.1.e001836.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2026061123350682000_5.1.e001836.10","doi-asserted-by":"crossref","unstructured":"Grace AG , Mittal A , Jain S , et al . Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2019.","DOI":"10.1002\/14651858.CD012918.pub2"},{"key":"2026061123350682000_5.1.e001836.11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir184"},{"key":"2026061123350682000_5.1.e001836.12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cpt.1102","article-title":"Forecasting Clinical Dose\u2013Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin","volume":"104","author":"Wicha","year":"2018","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026061123350682000_5.1.e001836.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102857","article-title":"Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis","volume":"77","author":"Haigh","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026061123350682000_5.1.e001836.14","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2502866","article-title":"Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis","volume":"393","author":"Meya","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061123350682000_5.1.e001836.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00361-2021"},{"key":"2026061123350682000_5.1.e001836.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.03.026"},{"key":"2026061123350682000_5.1.e001836.17","unstructured":"Tuberculosis: multidrug-resistant (MDR-TB) or rifampicin-resistant TB (RR-TB). Available: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb) [Accessed 22 May 2025]."},{"key":"2026061123350682000_5.1.e001836.18","doi-asserted-by":"crossref","unstructured":"Conradie F , Badat T , Poswa A , et al . BEAT tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis. Infectious Diseases (except HIV\/AIDS) [Preprint] 2025. doi:10.1101\/2025.05.04.25326549","DOI":"10.1101\/2025.05.04.25326549"},{"key":"2026061123350682000_5.1.e001836.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.02.043"},{"key":"2026061123350682000_5.1.e001836.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026061123350682000_5.1.e001836.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026061123350682000_5.1.e001836.22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026061123350682000_5.1.e001836.23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad312"},{"key":"2026061123350682000_5.1.e001836.24","first-page":"192","article-title":"Treatment of Drug-Resistant Tuberculosis with Bedaquiline, Pretomanid, Linezolid with or Without Moxifloxacin (BPaL\/M): Feasibility and Implementation Challenges in Western Canada","volume":"10","author":"Muir","year":"2025","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2026061123350682000_5.1.e001836.25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5588\/ijtldopen.24.0369","article-title":"Experience of piloting BPaLM\/BPaL for DR-TB care at selected sites in Pakistan","volume":"1","author":"Khan","year":"2024","journal-title":"IJTLD Open"},{"key":"2026061123350682000_5.1.e001836.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, Linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2026061123350682000_5.1.e001836.27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026061123350682000_5.1.e001836.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jctube.2024.100426","article-title":"Relapse after treatment with standardised all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and meta-analysis","volume":"35","author":"Reza Yosofi","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026061123350682000_5.1.e001836.29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101380","article-title":"Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026061123350682000_5.1.e001836.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-007182","article-title":"Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis","volume":"7","author":"Mulder","year":"2022","journal-title":"BMJ Glob Health"},{"key":"2026061123350682000_5.1.e001836.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001337","article-title":"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis","volume":"2","author":"Sweeney","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026061123350682000_5.1.e001836.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051521","article-title":"Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines","volume":"11","author":"Gomez","year":"2021","journal-title":"BMJ Open"},{"key":"2026061123350682000_5.1.e001836.33","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0085-2015"},{"key":"2026061123350682000_5.1.e001836.34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","article-title":"Bedaquiline, moxifloxacin, pretomanid and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial","volume":"7","author":"Tweed","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026061123350682000_5.1.e001836.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400327"},{"key":"2026061123350682000_5.1.e001836.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-024-03633-3","article-title":"Nine months of bedaquiline, linezolid, levofloxacin, clofazimine and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicentre, randomised, open-label non-inferiority trial in China","volume":"22","author":"Song","year":"2024","journal-title":"BMC Med"},{"key":"2026061123350682000_5.1.e001836.37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026061123350682000_5.1.e001836.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00811-2"},{"key":"2026061123350682000_5.1.e001836.39","doi-asserted-by":"crossref","unstructured":"Manalan K , Green N , Arnold A , et al . A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis. ERS International Congress 2020 abstracts; 2020:476. doi:10.1183\/13993003.congress-2020.476","DOI":"10.1183\/13993003.congress-2020.476"},{"key":"2026061123350682000_5.1.e001836.40","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2214-109X(22)00498-3","article-title":"Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial","volume":"11","author":"Rosu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026061123350682000_5.1.e001836.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1976OC"},{"key":"2026061123350682000_5.1.e001836.42","doi-asserted-by":"crossref","first-page":"e01684","DOI":"10.1128\/aac.01684-21","article-title":"Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061123350682000_5.1.e001836.43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","article-title":"Delpazolid in combination with bedaquiline, delamanid and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial","volume":"25","author":"Minja","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026061123350682000_5.1.e001836.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00213-0"},{"key":"2026061123350682000_5.1.e001836.45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/IDR.S499816","article-title":"Contezolid Harboured Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomised Early Bactericidal Activity Study","volume":"18","author":"Jiang","year":"2025","journal-title":"Infect Drug Resist"},{"key":"2026061123350682000_5.1.e001836.46","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2147\/IDR.S469509","article-title":"Contezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series","volume":"17","author":"Xiong","year":"2024","journal-title":"Infect Drug Resist"},{"key":"2026061123350682000_5.1.e001836.47","doi-asserted-by":"crossref","first-page":"e00796","DOI":"10.1128\/aac.00796-23","article-title":"A phase I study of the safety, tolerability and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects","volume":"67","author":"Yang","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061123350682000_5.1.e001836.48","doi-asserted-by":"crossref","first-page":"100952","DOI":"10.1016\/j.lanmic.2024.07.015","article-title":"Safety, bactericidal activity and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b\/2a trial","volume":"6","author":"Heinrich","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026061123350682000_5.1.e001836.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02829-7"},{"key":"2026061123350682000_5.1.e001836.50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202408-1632OC"},{"key":"2026061123350682000_5.1.e001836.51","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku553"},{"key":"2026061123350682000_5.1.e001836.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"2026061123350682000_5.1.e001836.53","doi-asserted-by":"crossref","first-page":"e02477","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026061123350682000_5.1.e001836.54","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0486"},{"key":"2026061123350682000_5.1.e001836.55","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0515"},{"key":"2026061123350682000_5.1.e001836.56","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202012-4541OC"},{"key":"2026061123350682000_5.1.e001836.57","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00064-21","article-title":"Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases","volume":"34","author":"Shaw","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"2026061123350682000_5.1.e001836.58","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2024.100015","article-title":"Emerging therapies and respiratory infections: Focus on the impact of immunosuppressants and immunotherapies","volume":"24","author":"Patterson","year":"2024","journal-title":"Clin Med (Lond)"},{"key":"2026061123350682000_5.1.e001836.59","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026061123350682000_5.1.e001836.60","first-page":"854","article-title":"Micronutrient supplements and mortality of HIV-infected adults with pulmonary TB: a controlled clinical trial","volume":"11","author":"Semba","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061123350682000_5.1.e001836.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61889-2"},{"key":"2026061123350682000_5.1.e001836.62","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02003-2018"},{"key":"2026061123350682000_5.1.e001836.63","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1093\/infdis\/jiaf069","article-title":"Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomised Pilot Trial","volume":"231","author":"Dekkers","year":"2025","journal-title":"J Infect Dis"},{"key":"2026061123350682000_5.1.e001836.64","doi-asserted-by":"crossref","unstructured":"Miow QH , Vallejo AF , Wang Y , et al . Doxycycline host-directed therapy in human pulmonary tuberculosis. J Clin Invest 2021;131. doi:10.1172\/JCI141895","DOI":"10.1172\/JCI141895"},{"key":"2026061123350682000_5.1.e001836.65","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300332","article-title":"Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis","volume":"3","author":"Wallis","year":"2024","journal-title":"NEJM Evidence"},{"key":"2026061123350682000_5.1.e001836.66","doi-asserted-by":"crossref","first-page":"602589","DOI":"10.3389\/fimmu.2020.602589","article-title":"Adjunct N-Acetylcysteine Treatment in Hospitalised Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial","volume":"11","author":"Safe","year":"2020","journal-title":"Front Immunol"},{"key":"2026061123350682000_5.1.e001836.67","doi-asserted-by":"crossref","unstructured":"Fonseca KL , Farr\u00e9s J , Barbakadze K , et al . NSAIDS-xdr-tb clinical trial: a randomized pilot study to estimate the potential efficacy and safety of using adjunctive ibuprofen for the treatment of pre-xdr and xdr tuberculosis. Infectious Diseases (except HIV\/AIDS) [Preprint] 2025. doi:10.1101\/2025.05.29.25328553","DOI":"10.1101\/2025.05.29.25328553"},{"key":"2026061123350682000_5.1.e001836.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00067-1"},{"key":"2026061123350682000_5.1.e001836.69","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.23.0190","article-title":"Atorvastatin improves sputum conversion and chest X-ray severity score","volume":"27","author":"Adewole","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061123350682000_5.1.e001836.70","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18200-5","article-title":"Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese Patients with Multidrug-resistant Tuberculosis","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"2026061123350682000_5.1.e001836.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104535"},{"key":"2026061123350682000_5.1.e001836.72","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2214-109X(25)00431-0","article-title":"Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis","volume":"14","author":"Mafirakureva","year":"2026","journal-title":"Lancet Glob Health"},{"key":"2026061123350682000_5.1.e001836.73","doi-asserted-by":"crossref","first-page":"107876","DOI":"10.1016\/j.ijid.2025.107876","article-title":"Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality","volume":"155","author":"Sossen","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026061123350682000_5.1.e001836.74","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1186\/s12879-025-11830-5","article-title":"Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031","volume":"25","author":"Feng","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026061123350682000_5.1.e001836.75","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4696"},{"key":"2026061123350682000_5.1.e001836.76","doi-asserted-by":"crossref","unstructured":"Bardal SK , Waechter JE , Martin DS . Infectious Diseases. Applied Pharmacology 2011;233\u201391. doi:10.1016\/B978-1-4377-0310-8.00018-X","DOI":"10.1016\/B978-1-4377-0310-8.00018-X"},{"key":"2026061123350682000_5.1.e001836.77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"key":"2026061123350682000_5.1.e001836.78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003008","article-title":"Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data","volume":"17","author":"Dean","year":"2020","journal-title":"PLoS Med"},{"key":"2026061123350682000_5.1.e001836.79","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026061123350682000_5.1.e001836.80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309352","article-title":"Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis","volume":"19","author":"Requena","year":"2024","journal-title":"PLoS One"},{"key":"2026061123350682000_5.1.e001836.81","doi-asserted-by":"crossref","unstructured":"Zhang Y , Shi W , Zhang W , et al . Mechanisms of Pyrazinamide Action and Resistance. Microbiol Spectr 2014;2. doi:10.1128\/microbiolspec.MGM2-0023-2013","DOI":"10.1128\/microbiolspec.MGM2-0023-2013"},{"key":"2026061123350682000_5.1.e001836.82","article-title":"A Global Perspective on Pyrazinamide Resistance","volume":"10","author":"Whitfield","year":"2015","journal-title":"Systematic Review and Meta-Analysis PLoS One"},{"key":"2026061123350682000_5.1.e001836.83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00162-09"},{"key":"2026061123350682000_5.1.e001836.84","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04933-14"},{"key":"2026061123350682000_5.1.e001836.85","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/antibiotics13070624","article-title":"Mutations in embB406 Are Associated with Low-Level Ethambutol Resistance in Canadian Mycobacterium tuberculosis Isolates","volume":"13","author":"Hiebert","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2026061123350682000_5.1.e001836.86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2049936116661962","article-title":"Primary ethambutol resistance among Iranian pulmonary tuberculosis patients: a systematic review","volume":"3","author":"Nasiri","year":"2016","journal-title":"Therapeutic Advances in Infection"},{"key":"2026061123350682000_5.1.e001836.87","unstructured":"UK Health Security Agency . Tuberculosis (TB): diagnosis, screening, management and data. 2024."},{"key":"2026061123350682000_5.1.e001836.88","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"2026061123350682000_5.1.e001836.89","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100128","article-title":"Pretomanid for tuberculosis treatment: an update for clinical purposes","volume":"3","author":"Occhineri","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026061123350682000_5.1.e001836.90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJME2208554"},{"key":"2026061123350682000_5.1.e001836.91","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00395-15"},{"key":"2026061123350682000_5.1.e001836.92","first-page":"1041","article-title":"Delamanid: First Global Approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026061123350682000_5.1.e001836.93","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00558-10"},{"key":"2026061123350682000_5.1.e001836.94","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02191-12"},{"key":"2026061123350682000_5.1.e001836.95","doi-asserted-by":"publisher","DOI":"10.1126\/science.8284673"},{"key":"2026061123350682000_5.1.e001836.96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.475798"},{"key":"2026061123350682000_5.1.e001836.97","doi-asserted-by":"crossref","first-page":"e00613","DOI":"10.1128\/aac.00613-24","article-title":"Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects","volume":"68","author":"Lombardi","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061123350682000_5.1.e001836.98","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae176"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-001836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:35:34Z","timestamp":1781246134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjmed-2025-001836"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-001836","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}